A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease

Journal of Clinical Investigation

Volumn 100, Issue 5, 1997, Pages 1059-1070

  Wu, Jianming ^a   Edberg, Jeffrey C ^a   Redecha, Patricia B ^b   Bansal, Vipin ^a   Guyre, Paul M ^c   Coleman, Kimberly ^c   Salmon, Jane E ^b   Kimberly, Robert P ^a  

^a The University of Alabama at Birmingham   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Fc; Genetics; Killer cells; Lupus erythematosus; Macrophages; Natural; Polymorphism; Receptors; Systemic

Indexed keywords

CALCIUM ION; CD16 ANTIGEN; EPITOPE; FC RECEPTOR; IMMUNOGLOBULIN G;

ARTICLE; AUTOIMMUNITY; CALCIUM CELL LEVEL; DNA POLYMORPHISM; FLOW CYTOMETRY; GENETIC SUSCEPTIBILITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; NUCLEIC ACID BASE SUBSTITUTION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOIMMUNE DISEASE; CHEMISTRY; GENETIC POLYMORPHISM; METABOLISM; PHYSIOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; AUTOIMMUNE DISEASES; EPITOPES; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; POLYMORPHISM, GENETIC; RECEPTORS, IGG;

EID: 0030611089     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119616     Document Type: Article

References (63)

1. Clark, M.R., S.B. Clarkson, P.A. Ory, N. Stollman, and I.M. Goldstein. 1989. Molecular basis for a polymorphism involving Fcγ receptor II on human monocytes. J. Immunol. 143:1731-1734.
2. Warmerdam, P.A.M., J.G.J. van de Winkel, E.J. Gosselin, and P.J.A. Capel. 1990. Molecular basis for a polymorphism of human Fcγ receptor II (CD32). J. Exp. Med. 172:19-25.
3. - COS cells. Immunol. Cell Biol. 70:79-87.
4. Clark, M.R., S.G. Stuart, R.P. Kimberly, P.A. Ory, and I.M. Goldstein. 1991. A single amino acid distinguishes the high responder from the low responder form of Fcγ receptor II on human monocytes. Eur. J. Immunol. 21: 1911-1916.
5. Scallon, B.J., E. Scigliano, V.H. Freedman, M.C. Miedel, Y.-C.E. Pan, J.C. Unkeless, and J.P. Kochan. 1989. A human immunoglobulin G receptor exists in both polypeptide-anchored and phosphatidylinositol-anchored forms. Proc. Natl. Acad. Sci. USA. 86:5079-5083.
6. Peltz, G.A., H.O. Grundy, R.V. Lebo, H. Yssel, G.S. Barsh, and K.W. Moore. 1989. Human FcγRIII: cloning, expression and identification of the chromosomal locus of the two Fcγ receptors for IgG. Proc. Natl. Acad. Sci. USA. 86:1013-1017.
7. Ory, P.A., M.R. Clark, E.E. Kwoh, S.B. Clarkson, and I.M. Goldstein. 1989. Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fcγ receptor III on human neutrophils. J. Clin. Invest. 84:1688-1692.
8. Huizinga, T.W.J., M. Kleijer, P.A. Tetteroo, D. Roos, and A.E.G.K. von dem Borne. 1990. Biallelic neutrophil NA-antigen system is associated with a polymorphism on the phosphoinositol-linked Fcγ receptor III (CD16). Blood. 75:213-217.
9. Salmon, J.E., J.C. Edberg, and R.P. Kimberly. 1990. Fcγ receptor III on human neutrophils. Allelic variants have functionally distinct capacities. J. Clin. Invest. 85:1287-1295.
10. Salmon, J.E., J.C. Edberg, N.L. Brogle, and R.P. Kimberly. 1992. Allelic polymorphisms of human Fcγ receptor IIA and Fcγ receptor IIIB. Independent mechanisms for differences in human phagocyte function. J. Clin. Invest. 89: 1274-1278.
11. Salmon, J.E., S.S. Millard, N.L. Brogle, and R.P. Kimberly. 1995. Fcγ receptor IIIb enhances Fcγ receptor IIa function in an oxidant dependent and allele-sensitive manner. J. Clin. Invest. 95:2877-2885.
12. Parren, P.W.H.I., P.A.M. Warmerdam, L.C.M. Boeije, J. Arts, N.A.C. Westerdaal, A. Vlug, P.J.A. Capel, L.A. Aarden, and J.G.J. van de Winkel. 1992. On the interaction of IgG subclasses with the low-affinity FcγRIIa (CD32) on human monocytes, neutrophils, and platelets. J. Clin. Invest. 90:1537-1546.
13. Bredius, R.G.M., C.A.P. Fijen, M. de Haas, E.J. Kuijper, R.S. Weening, J.G.J. van de Winkel, and T.A. Out. 1994. Role of neutrophil FcγRII (CD32) and FcγRIIIb (CD16) polymorphic forms in phagocytosis of human IgG1-and IgG3-opsonized bacteria and erythrocytes. Immunology. 83:624-630.
14. Sanders, L.A.M., J.G.J. van de Winkel, G.T. Rijkers, M.M. VoorhorstOgink, M. de Haas, P.J. Capel, and B.J. Zegers. 1994. Fcγ receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J. Infect. Dis. 170:854-860.
15. Bredius, R.G.M., B.H.F. Derkx, C.A.P. Fijen, T.P. de Wit, M. de Haas, R.S. Weening, and J.G.J. van de Winkel. 1994. Fcγ receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J. Infect. Dis. 170:848-853.
16. Salmon, J.E., S. Millard, L.A. Schacter, F.C. Arnett, E.M. Ginzler, M.F. Gourley, R. Ramsey-Goldman, and R.P. Kimberly. 1996. FcγRIIA alleles are heritable risk factors for lupus nephritis in African-Americans. J. Clin. Invest. 97:1348-1354.
17. Duits, A.J., H. Bootsma, R.H.W.M. Derksen, P.E. Spronk, L. Kater, G.G.M. Kallenberg, P.J.A. Capel, N.A.C. Westerdaal, G.T. Spierenbury, F.H.J. Gmelig-Meyling, and J.G.J. van de Winkel. 1995. Skewed distribution of IgG Fcγ receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum. 39:1832-1836.
18. Botto, M., E. Theodoridis, E.M. Thompson, H.L. Beynon, D. Briggs, D.A. Isenberg, M.J. Walport, and K.A. Davies. 1996. FcγRIIa polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clin. Exp. Immunol. 104:264-268.
19. Fijen, C.A.P., R.G.M. Bredius, and E.J. Kuijper. 1993. Polymorphism of IgG Fcγ receptors in meningococcal disease: risk marker in complement deficient patients. Ann. Intern. Med. 119:636-641.
20. Wainstein, E., J. Edberg, E. Csernok, M. Sneller, G. Hoffman, E. Keystone, W. Gross, J. Salmon, and R. Kimberly. 1996. FcγRIIIB alleles predict renal dysfunction in Wegeners Granulomatosis (WG). Arthritis Rheum. 39:S210.
21. Ravetch, J.V., and B. Perussia. 1989. Alternative membrane forms of FcγRIII (CD16) on human NK cells and neutrophils. Cell-type specific expression of two genes which differ in single nucleotide substitutions. J. Exp. Med. 170:481-497.
22. Radeke, H.H., J.E. Gessner, P. Uciechowski, H.J. Magert, R.E. Schmidt, and K. Resch. 1994. Intrinsic human glomerular mesangial cells can express receptors for IgG complexes (hFcγRIII-A) and the associated Fc∈RI γ-chain. J. Immunol. 153:1281-1292.
23. Vance, B.A., T.W.J. Huizinga, K. Wardwell, and P.M. Guyre. 1993. Binding of monomeric human IgG defines an expression polymorphism of FcγRIII on large granular lymphocyte/natural killer cells. J. Immunol. 151: 6429-6439.
24. de Haas, M., H.R. Koene, M. Kleijer, E. de Vries, S. Simsek, M.J.D. van Tol, D. Roos, and A.E.G.K. von dem Borne. 1996. A triallelic Fcγ receptor type IIIA polymorphism influences the binding of human IgG by NK cell FcγRIIIA. J. Immunol. 156:2948-2955.
25. Koene, H.R., M. de Haas, D. Roos, and A.E.G.K. von dem Borne. 1996. Soluble FcγRIII: biology and clinical implications. In Human IgG Fc Receptors. J.G.J. van de Winkel and P.J.A. Capel, editors. R.G. Landes Co., Austin, TX. 181-193.
26. Jawahar, S., C. Moody, M. Chan, R. Finberg, R. Geha, and T. Chatila. 1996. Natural killer (NK) cell deficiency associated with an epitope-deficient Fcγ receptor type IIIA (CD16-II). Clin. Exp. Immunol. 103:408-413.
27. Hulett, M.D., and P.M. Hogarth. 1994. Molecular basis of Fc receptor function. Adv. Immunol. 57:1-124.
28. Hibbs, M.L., M. Tolvanen, and O. Carpen. 1994. Membrane-proximal Ig-like domain of FcγRIII (CD16) contains residues critical for ligand binding. J. Immunol. 152:4466-4474.
29. Hulett, M.D., E. Witort, R.I. Brinkworth, I.F.C. McKenzie, and P.M. Hogarth. 1995. Multiple regions of human FcγRII (CD32) contribute to the binding of IgG. J. Biol. Chem. 270:21188-21194.
30. Tamm, A., A. Kister, K.U. Nolte, J.E. Gessner, and R.E. Schmidt. 1996. The IgG binding site of human FcγRIIIB receptor involves CC′ and FG loops of the membrane-proximal domain. J. Biol. Chem. 271:3659-3666.
31. Perussia, B., S. Starr, S. Abraham, V. Fanning, and G. Trinchieri. 1983. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fcγ receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J. Immunol. 130:2133-2144.
32. Tamm, A., and R.E. Schmidt. 1996. The binding epitopes of human CD16 (FcγRIII) monoclonal antibodies. Implications for ligand binding. J. Immunol. 157:1576-1581.
33. Tan, E.M., A.S. Cohen, J.F. Fries, A.T. Masi, D.J. McShane, N.F. Rothfield, J.G. Shaller, N. Talal, and R.J. Winchester. 1982. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25:1271-1277.
34. Fleit, H.B., C.D. Kobasiuk, N.S. Peress, and A. Fleit. 1992. A common epitope is recognized by monoclonal antibodies against purified human neutrophil FcγRIII (CD16). Clin. Immunol. Immunopathol. 62:16-24.
35. Edberg, J.C., and R.P. Kimberly. 1992. Receptor specific probes for the study of individual Fcγ receptor function. J. Immunol. Methods. 148:179-187.
36. Holmes, K., B.J. Fowlkes, I. Schmid, and J.V. Giorgi. 1992. Preparation of cells and reagents for flow cytometry. In Current Protocols in Immunology. J.E. Cooligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevatch, and W. Strobe, editors. John Wiley & Sons Inc., New York. 5.3.5-5.3.6.
37. 2+], flux by distinct regions of an Fcγ receptor. Science (Wash. DC). 254:1785-1788.
38. PMN mediates transmembrane signaling events distinct from FcγRII. J. Exp. Med. 171:1239-1255.
39. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:3440-3450.
40. Anegon, I., M.C. Cuturi, G. Trinchieri, and B. Perussia. 1988. Interaction of Fcγ receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J. Exp. Med. 167:452-461.
41. Harris, D.T., W.W. Travis, and H.S. Koren. 1989. Induction of activation antigens on human natural killer cells mediated through the Fcγ receptor. J. Immunol. 143:2401-2406.
42. Ortaldo, J.R., A.T. Mason, and J.J. O'Shea. 1995. Receptor-induced death in human natural killer cells: involvement of CD16. J. Exp. Med. 181: 339-344.
43. Azzoni, L., I. Anegon, R. Calabretta, and B. Perussia. 1995. Ligand binding to FcγR induces c-myc-dependent apoptosis in IL-2 stimulated NK cells. J. Immunol. 154:491-499.
44. Eischen, C.M., J.D. Schilling, D.H. Lynch, P.H. Krammer, and P.J. Leibson. 1996. Fcγ receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytoloxicity and subsequent autocrine NK cell apoptosis. J. Immunol. 156:2693-2699.
45. Darzynkiewicz, Z., X. Li, J. Gong, and F. Traganos. 1997. Methods for analysis of apoptosis by flow cytometry. In Manual of Clinical Laboratory Immunology. 5th edition. N.R. Rose, editor. ASM Press, Washington, DC. 334-343.
46. de Haas, M., M. Kleijer, D. Roos, and A.E.G.K. von dem Borne. 1994. Characterization of mAbs of the CD16 cluster and six newly generated CD16 mAbs. In Leukocyte Typing V: White Cell Differentiation Antigens. S.F. Schlossman, L. Boumsell, and W. Gilks, editors. Oxford University Press. 811-814.
47. Trounstine, M.L., G.A. Peltz, H. Yssel, T.W. Huizinga, A.E.G.K. von dem Borne, H. Spits, and K.W. Moore. 1990. Reactivity of cloned, expressed human FcγRIII isoforms with monoclonal antibodies which distinguish cell-type-specific and allelic forms of FcγRIII. Int. Immunol. 2:303-310.
48. 2+ mobilization and phosphoinositide turnover in human natural killer cells. J. Exp. Med. 169:439-467.
49. Gismondi, A., F. Mainiero, S. Morrone, G. Palmieri, M. Piccoli, L. Frati, and A. Santoni. 1992. Triggering through CD16 or phorbol esters enhances adhesion of NK cells to laminin via very late antigen 6. J. Exp. Med. 176:1251-1257
50. Takai, T., M. Ono, M. Hikida, H. Ohmori, and J.V. Ravetch. 1996. Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature (Lond.). 379:346-349.
51. Luan, J.J., R.C. Monteiro, C. Sautes, G. Fluteau, L. Eloy, W.H. Fridman, J.-F. Bach, and H.-J. Garchon. 1996. Defective FcγRII gene expression in macrophages of NOD mice. Genetic linkage with up-regulation of IgG1 and IgG2b in serum. J. Immunol. 157:4707-4716.
52. de Haas, M., M. Kleijer, R.M. Minchinton, D. Roos, and A.E.G.K. von dem Borne. 1994. Soluble FcγRIIIa is present in plasma and is derived from natural killer cells. J. Immunol. 152:900-907.
53. Harrison, D., J.H. Phillips, and L.L. Lanier. 1991. Involvement of a metalloprotease in spontaneous and phorhol ester-induced release of natural killer cell-associated FcγRIII (CD16-II). J. Immunol. 147:3459-3465.
54. Fleit, H.B., C.D. Kobasiuk, C. Daly, R. Furie, P.C. Levy, and R.O. Webster. 1992. A soluble form of FcγRIII is present in human serum and other body fluids and is elevated at sites of inflammation. Blood. 79:2721-2728.
55. Teillaud, C., J. Galon, M.-T. Zilber, N. Mazieres, R. Sasgnoli, R. Kurrle, W.H. Fridman, and C. Sautes. 1993. Soluble CD16 binds peripheral blood mononuclear cells and inhibits pokeweed-mitogen-induced responses. Blood. 82:3081-3090.
56. Hoover, R.G., C. Lary, R. Page, P. Travis, R. Ownes, J. Flick, J. Kornbluth, and B. Baslogie. 1995. Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16. J. Clin. Invest. 95:241-247.
57. Wing, M.G., T. Moreau, J. Greenwood, R.M. Smith, G. Hale, J. Isaacs, H. Waldmann, P.J. Lachmann, and A. Compstom. 1996. Mechanism of first-dose cvtokine-release syndrome by CAMPATH 1-H. Involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest. 98:2819-2826.
58. Clarkson, S.B., R.P. Kimberly, J.E. Valinsky, M.D. Witmer, J.B. Bussel, R.L. Nachman, and J.C. Unkeless. 1986. Blockade of clearance of immune complexes by an atii-Fcγ receptor monoclonal antibody. J. Exp. Med. 164:474-489.
59. Kimberly, R.P., J.C. Edberg, L.T. Merriam, S.B. Clarkson, J.C. Unkeless, and R.P. Taylor. 1989. The in vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees. J. Clin. Invest. 84:962-970.
60. Hazenbos, W.L.W., J.G.E. Gessner, F.M.A. Hofhuis, H. Kuipers, D. Meyer, I.A.F.M. Heijnen, R.E. Schmidt, M. Sandor, P.J.A. Capel, M. Daëron, et al. 1996. Impaired IgG-dependent anaphylaxis and arthus reaction in FcγRIII (CD16) deficient mice. Immunity. 5:181-188.
61. Kimberly, R.P., J.E. Salmon, and J.C. Edberg. 1995. Receptors for immunoglobulin G. Molecular diversity and implications for disease. Arthritis Rheum. 38:306-314.
62. Harley, J.B., P. Sheldon, B. Neas, S. Murphy, D.H. Wallace, R.H. Scofield, T.S. Shaver, and K.L. Hardgrave-Moser. 1994. Systemic lupus erythematosus. Considerations for a genetic approach. J. Invest. Dermatol. 103:144-149.
63. Tsao, B.P., R.M. Cantor, K.C. Kalunian, C.-J. Chen, H. Badsha, R. Singh, D.J. Wallace, R.C. Kitridou, S.-I. Chen, N. Shen, Y.W. Song, D.A. Isenberg, C.-L. Yu, B.H. Hahn, and J.I. Rotter. 1997. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J. Clin. Invest. 99:725-731.